Memantina Mabo

Memantine Hydrochloride, the active ingredient in Memantina Mabo, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantina Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Mabo is a NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease and related cognitive disorders. - Moderate to severe Alzheimer’s disease: improves cognition, daily functioning and global clinical status. - Mild to moderate Alzheimer’s disease (as adjunct to cholinesterase inhibitors): may provide additional cognitive benefit. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with the condition.

Memantina Mabo may be associated with a range of adverse reactions.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial discomfort. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or lack of energy. - Confusion: temporary disorientation or difficulty concentrating.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hallucinations: visual or auditory disturbances. - Hyponatremia: low blood sodium levels, potentially causing weakness or confusion.

Before prescribing Memantina Mabo, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor renal function in patients with reduced kidney function. - Hepatic disease: use with caution in patients with liver dysfunction. - History of seizures: evaluate risk as memantine may lower seizure threshold. - Concomitant use with other NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Memantina Mabo can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuro‑psychiatric adverse effects. - Ketamine: additive NMDA blockade can exacerbate CNS depression.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): monitor for enhanced cognitive effects. - Diuretics (e.g., furosemide): may increase risk of hyponatremia. - CNS depressants (e.g., benzodiazepines): observe for increased sedation.